IOVAIovance Biotherapeutics, Inc.
$14.61+613% 1Y
$14.61
$1.8152 weeks$14.79
The financials
Iovance Biotherapeutics, Inc. by the numbers
Iovance Biotherapeutics, Inc. (IOVA) reported revenue of $99M in Q2 2026 (quarter ended Jun 30, 2026), up 66% from the same quarter a year earlier. That came with a gross margin of 56% and net loss of $47M. For the full year FY2025, revenue was $264M (+61% year on year) and net income −$391M. Its largest product in Q2 2026 was Amtagvi at $91M, 91% of the disclosed total, well ahead of Proleukin at 8.7%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $99M | $60M | +66% |
| Gross profit | $56M | $11M | +403% |
| Operating income | −$52M | −$114M | n/a |
| Net income | −$47M | −$112M | n/a |
| Diluted EPS | −$0.11 | −$0.33 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Amtagvi | $91M | 91% |
| Proleukin | $8.6M | 8.7% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $99.3M (+39%)
Amtagvi grew +68% year on yearProleukin +46% year on year
Segment Latestquarter on quarteryear on year
- Amtagvi$90.7M$90.7Mquarter on quarter +51%year on year +68%+51%+68%
- Proleukin$8.6M$8.6Mquarter on quarter -23%year on year +46%-23%+46%
On our screens:Most shorted stocks